

FIRST CLINICAL CASE REPORT

Ochromobacter intermedium: an emerging opportunistic pathogen—case of recurrent bacteraemia associated with infective endocarditis in a haemodialysis patient

T. Bharucha^{1,2}, D. Sharma¹, H. Sharma¹, H. Kandil³ and S. Collier¹

1) Royal Free Hospital NHS Foundation Trust, 2) University College London, London and 3) West Hertfordshire NHS Foundation Trust, Stevenage, UK

Abstract

We describe the first clinical case report of infective endocarditis related to *Ochromobacter intermedium* infection. The case involved a 23-year-old man receiving dialysis via an internal jugular long-term haemodialysis catheter. He improved with a prolonged course of meropenem and minocycline. *Ochromobacter* spp. are recognized as rare emerging opportunistic pathogens.

© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Original Submission: 10 May 2016; **Revised Submission:** 28 September 2016; **Accepted:** 30 September 2016

Article published online: 6 October 2016

Corresponding author: T. Bharucha, Microbiology Department, Royal Free Hospital NHS Foundation Trust, Pond Street, London NW3 2QG, UK
E-mail: t.bharucha@doctors.org.uk

A 23-year-old male haemodialysis patient attended the emergency department with fever and rigors 10 days after a 2-week visit to Pakistan. He had bilateral renal dysplasia, with a failed renal transplant while receiving immunosuppression, and was undergoing dialysis via a right internal jugular long-term haemodialysis catheter. He had received maintenance haemodialysis at a medical centre in Pakistan.

On examination, his blood pressure was 99/37 mm Hg, pulse 140 beats per minute and temperature 37.7°C. General examination was unremarkable, with no features of infective endocarditis noted. Investigations revealed a white blood cell count of $7 \times 10^9/L$, C-reactive protein of 146 mg/L and normal chest X-ray. In the absence of an obvious septic focus, he received intravenous (iv) flucloxacillin and gentamicin for catheter-related septicaemia as per hospital guidelines.

Admission blood culture (BC) of samples taken from the long-term haemodialysis catheter were positive at 24 hours with Gram-negative rods identified as *Ochromobacter* spp. by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Microflex, Biotyper

3.1; Bruker Daltonics, Bremen, Germany) and *O. intermedium* by the reference laboratory by partial sequencing of the 16S ribosomal RNA gene. Repeat long-term haemodialysis catheter BC of samples taken 24 and 48 hours after admission and peripheral BC of samples taken 96 hours after admission remained positive for *Ochromobacter* spp. The catheter was removed, and antibiotic therapy was switched to meropenem 1 g iv twice daily, to continue 48 hours after line removal. He improved and was discharged.

Two months later he again sought care for fever and shortness of breath. At examination he had pulmonary oedema with a raised C-reactive protein of 79 mg/L. BC of samples taken at admission grew *Ochromobacter* spp. after 31 hours. On the basis of reference laboratory susceptibilities he was treated with meropenem 1 g iv twice daily and tigecycline 50 mg iv twice daily. Transthoracic echocardiography demonstrated a 1.32 cm² right atrial vegetation. He developed sudden hypoxia, and computed tomographic pulmonary angiography revealed a right lung pulmonary embolus; he commenced anticoagulation therapy. Five days later he developed abdominal pain with amylase 267 U/L. Computed tomography confirmed pancreatitis. Because of this recognized tigecycline complication, tigecycline was switched to minocycline 100 mg iv twice daily. He was discharged 2 weeks later to complete 6 weeks of treatment with meropenem and minocycline. Repeated BC analyses have since been negative.

TABLE I. *Ochrobactrum intermedium* isolates with antibiotic susceptibility in chronological order

Date	Source	Conditions	Identification	Susceptibility (in house)		
				Antibiotic	MIC	Interpretation
25/9/15	iv line	Aerobic BACTEC bottle after 25 hours	<i>Ochrobactrum intermedium</i> (laboratory reference)	Ciprofloxacin	2	Intermediate
				Amikacin	>256	Resistant
				Colistin	>256	Resistant
				Meropenem	>32	Resistant
26/9/15	iv line	Aerobic BACTEC bottle after 24 hours	<i>Ochrobactrum</i> spp.	Not performed	—	—
27/9/15	iv line	Aerobic BACTEC bottle after 15 hours	<i>Ochrobactrum</i> spp.	Not performed	—	—
29/9/15	Peripheral	Aerobic BACTEC bottle after 21 hours	<i>Ochrobactrum</i> spp.	Not performed	—	—
21/11/15	iv line	Aerobic BACTEC bottle after 33 hours	<i>Ochrobactrum intermedium</i>	Ertapenem	0.5	Susceptible
				Meropenem	1.5	Susceptible
				Tigecycline	1.5	Susceptible
				Ciprofloxacin	4	Resistant
				Colistin	>256	Resistant
				Fosfomicin	>1024	Resistant
24/11/15	iv line	Aerobic BACTEC bottle after 31 hours	<i>Ochrobactrum</i> spp.	Tigecycline	1.5	Susceptible
				Ertapenem	1.5	Intermediate
				Meropenem	3	Intermediate
				Colistin	>256	Resistant
				Imipenem	12	Resistant
				Cotrimoxazole	6	Resistant
				Ciprofloxacin	6	Resistant

iv, intravenous; MIC, minimum inhibitory concentration.

Ochrobactrum spp. are non-lactose-fermenting, Gram-negative rods that belong to the genus *Brucella*. The most common species identified is *Ochrobactrum anthropi* [1,2]. They are widely regarded as environmental pathogens with low virulence [3,4].

There is minimal literature on infections caused by *O. intermedium*, and none is associated with intravascular infection. *Ochrobactrum* spp. infections largely relate to immunocompromised patients with bacteraemias, endophthalmitis and a pyogenic liver abscess [5–8]. Notably, this is the first documented case of infective endocarditis related to *O. intermedium* in humans. Successful therapy has been achieved with combination antibiotic therapy based on known susceptibilities, including imipenem with ciprofloxacin/tobramycin (Table I).

There are few data to inform treatment or interpret minimum inhibitory concentration (MIC) breakpoints. Reported resistance to penicillins and cephalosporins is widespread, with susceptibility to aminoglycosides, fluoroquinolones, imipenem, meropenem, tetracycline and cotrimoxazole. MICs to carbapenems may rise after carbapenem exposure. *O. anthropi* is generally susceptible to colistin, whereas *O. intermedium* is resistant. Resistance mechanisms are unclear and are possibly due to class C β -lactamases.

To our knowledge, this is the first case of infective endocarditis in an immunocompromised patient related to the emerging opportunistic pathogen *O. intermedium*. We advise colleagues to remain vigilant to the virulence potential of this organism, especially if it is recurrent and occurs in immunocompromised patients.

Conflict of Interest

None declared.

References

- [1] Bathe S, Achouak W, Hartmann A, Heulin T, Schloter M, Leuhn M. Genetic and phenotypic microdiversity of *Ochrobactrum* spp. FEMS Microbiol Ecol 2006;56:272–80.
- [2] Velasco J, Romero C, López-Goñi I, Leiva J, Díaz R, Moriyón I. Evaluation of the relatedness of *Brucella* spp. and *Ochrobactrum anthropi* and description of *Ochrobactrum intermedium* sp. nov., a new species with a closer relationship to *Brucella* spp. Int J Syst Bacteriol 1998;48(Pt 3):759–68.
- [3] Aujoulat F, Romano-Bertrand S, Masnou A, Marchandin H, Jumas-Bilak E. Niches, population structure and genome reduction in *Ochrobactrum intermedium*: clues to technology-driven emergence of pathogens. PLoS One 2014;9:e83376.
- [4] Kulkarni GJ, Shetty S, Dharne MS, Shouche YS. Genome sequencing analysis reveals virulence-related gene content of *Ochrobactrum intermedium* strain 229E, a urease-positive strain isolated from the human gastric niche. FEMS Microbiol Lett 2014;359:12–5.
- [5] Apisarnthanaraka A, Kiratisinb P, Mundyc LM. Evaluation of *Ochrobactrum intermedium* bacteremia in a patient with bladder cancer. Diagn Microbiol Infect Dis 2005;53:153–5.
- [6] Jacobs DJ, Grube TJ, Flynn Jr HW, Greven CM, Pathengay A, Miller D, et al. Intravitreal moxifloxacin in the management of *Ochrobactrum intermedium* endophthalmitis due to metallic intraocular foreign body. Clin Ophthalmol 2013;7:1727–30.
- [7] Möller LV, Arends JP, Harmsen HJ, Talens A, Terpstra P, Slooff MJ. *Ochrobactrum intermedium* infection after liver transplantation. J Clin Microbiol 1999;37:241–4.
- [8] Vaidya SA, Citron DM, Fine MB, Murakami G, Goldstein EJ. Pelvic abscess due to *Ochrobactrum intermedium* [corrected] in an immunocompetent host: case report and review of the literature. J Clin Microbiol 2006;44:1184–6. Erratum in: J Clin Microbiol 2007;45:1672.